| Radioactive iodine-refractory differentiated thyroid cancer and redifferentiation therapy J Liu, Y Liu, Y Lin, J Liang Endocrinology and Metabolism 34 (3), 215-225, 2019 | 97 | 2019 |
| Long-term results of a phase II trial of apatinib for progressive radioiodine refractory differentiated thyroid cancer YS Lin, X Zhang, C Wang, YQ Liu, WM Guan, J Liang The Journal of Clinical Endocrinology & Metabolism 106 (8), e3027-e3036, 2021 | 18 | 2021 |
| Unfavorable responses to radioiodine therapy in N1b papillary thyroid cancer: a propensity score matching study YQ Liu, H Li, JR Liu, YS Lin Endocrine Practice 25 (12), 1286-1294, 2019 | 9 | 2019 |
| Inferior vena cava tumor thrombus from thyroid cancer detected by 68Ga-PSMA-617 PET/CT H Li, Y Liu, J Zang, Z Yang, Y Lin Clinical Nuclear Medicine 46 (3), 264-265, 2021 | 2 | 2021 |
| Emerging management and its impact on radioiodine refractory differentiated thyroid cancer Y LIU, Y LIN Chinese Journal of Practical Surgery, 216-220, 2019 | 2 | 2019 |
| Select EZH2 inhibitors enhance viral mimicry effects of DNMT inhibition through a mechanism involving NFAT: AP-1 signaling AA Chomiak, RL Tiedemann, Y Liu, X Kong, Y Cui, AK Wiseman, ... Science Advances 10 (13), eadk4423, 2024 | 1 | 2024 |
| Reactions to COVID-19: actions of nuclear medicine healthcare personnel in China YQ Liu, Z Yang, YS Lin European Journal of Nuclear Medicine and Molecular Imaging 47 (8), 1798-1801, 2020 | 1 | 2020 |
| Significance of Dynamic Risk Assessment in the Follow-up of Non-distant Metastatic Differentiated Thyroid Cancer Patients with Intermediate and High Risk JR Liu, YQ Liu, H Li, J Liang, YS Lin Zhongguo yi xue ke xue Yuan xue bao. Acta Academiae Medicinae Sinicae 42 (2 …, 2020 | 1 | 2020 |
| An exploratory phase II clinical trial of apatinib in progressive radioiodine refractory differentiated thyroid cancer. YS Lin, X Zhang, Y Liu, C Wang, T Zhang Journal of Clinical Oncology 36 (15_suppl), e18094-e18094, 2018 | 1 | 2018 |
| Clinical analysis of short-term outcome in low-to-intermediate-risk thyroid cancer after low-dose 131I therapy S Juanjuan, LIU Yanqing, LIN Yansong China Oncology 29 (3), 207-211, 2019 | | 2019 |
| Performance comparison of intelligent recurrence-risk stratification software based on 2009 American Thyroid Association guidelines and 2014 Chinese guidelines for 131I therapy … H HU, J Liang, T Zhang, H LI, Y Liu, Y Lin Chinese Journal of Nuclear Medicine and Molecular Imaging, 271-273, 2018 | | 2018 |
